The company is now seeking commercial partners in Brazil to make the Iona test available in the country.
Adam Wolfberg argued that while corporate conflicts are widely discussed, physicians also have financial conflicts that can bias them against new technology.
Poor women have limited access to noninvasive prenatal screening tools, a post at Health Affairs' blog says.
The China Food and Drug Administration had also previously accredited both the NIFTY test and the BGISEQ sequencing platform.
The Singaporean firm already offers cell-free NIPT testing through its iGene Laboratory and sells a kit to test ovarian cysts for malignancy.
Reuters reports that UK researchers have tested a new approach to screening for Down syndrome and other chromosomal disorders.
The Chinese Academy of Sciences-led team said the approach could lead to a therapeutic strategy for human aneuploidy diseases involving additional chromosomes.
In a study involving almost 23,000 women, DNA reflex testing detect 95 percent of trisomies while avoiding recalls.
Denmark-based Arcedi would like to commercialize its technology through a major diagnostic company.
Funded by Biogen, The University of Colorado, and The Global Down Syndrome Foundation, the project will analyze genetics and other biology in 1,000 individuals with the disorder.
CNN reports that researchers have tied a new variant to opioid addiction risk.
Organoids derived from patients' tumors may help determine what chemotherapy treatment patients would benefit from, according to New Scientist.
An initiative from GenomeAsia 100K hopes to increase the number of South Asians in genetic research, according to NBC News.
In Science this week: genomic analysis of ancient and modern horses indicates population turnover, and more.